Last updated: April 24, 2026
What is barusiban and what is its clinical status?
Barusiban is a small-molecule antagonist of the human neurokinin-1 (NK-1) receptor. In clinical development, it was pursued for disorders where NK-1 pathway signaling was linked to symptom burden, with the clearest historical program emphasis in gynecology (preterm labor) and pain-related indications.
Program headline from prior development: barusiban has progressed through Phase 2 and later-stage studies in preterm labor cohorts, including trials designed around uterine contraction and gestational outcomes. Public regulatory and company communications around the program have been limited compared with peers, and the development timeline has not translated into a marketed product.
What do the most cited datasets show on efficacy and dosing in Phase 2?
Across publicly referenced clinical evaluations, barusiban dosing was studied to reduce uterine activity and improve pregnancy-related outcomes. In Phase 2-level designs, endpoints typically included reductions in frequency of contractions and composite obstetric outcomes, such as progression to delivery and neonatal outcomes.
Key characteristics of barusiban’s trial approach (as reported in literature and registries):
- Mechanism: NK-1 receptor antagonism (small molecule)
- Trial setting: obstetric indications centered on preterm labor physiology
- Primary logic: reduce uterine contractility via pathway blockade
- Endpoint types: uterine activity metrics and pregnancy continuation outcomes
Where is barusiban in development now?
Barusiban has not reached market authorization in any major jurisdiction based on publicly available regulatory and label data. The product has remained in the category of discontinued or deprioritized pipeline assets in the public domain, with no confirmed current global Phase 3 program or marketing authorization pathway disclosed in mainstream registries and evidence summaries.
Implication for investors and partners: the probability of near-term commercialization hinges on re-activation of a late-stage program, new clinical differentiation, or a new partnering strategy with a clearly defined regulatory path.
How does barusiban’s competitive landscape shape market upside?
What are the main competitive classes in the target space?
Historically, barusiban’s preterm labor positioning faced competition from:
- Tocolytics used to delay delivery (including nitric oxide synthase targeting agents, calcium channel blockers, and prostaglandin pathway modulators depending on geography and guideline eras)
- Steroid and perinatal-neonatal interventions that improve neonatal outcomes even when tocolysis fails
- Protocol-driven care that can reduce the incremental addressable benefit available to a new tocolytic antagonist
What does this mean for peak sales potential?
For a tocolytic-like product, peak market share is constrained by:
- Guideline variability by country and clinician preference
- The intensity of non-drug interventions and bundled obstetric protocols
- Narrow treatment windows that cap utilization rates
Given the absence of a clear, active late-stage program in public records, barusiban’s realistic market scenario is a partner-led relaunch with a differentiated endpoint claim and a modernized comparative trial plan.
What is the market projection for barusiban?
Because barusiban has no current approved label and no confirmed active Phase 3 program in mainstream registries, any market projection must be framed as a scenario estimate tied to commercialization likelihood. The most decision-relevant approach for an investment or partner deal is to model three scenarios for time-to-market and adoption.
Market sizing logic used for the projection
The projection focuses on the preterm labor addressable population and the probability-weighted penetration of a tocolytic-class therapy. The key drivers are:
- Annual preterm labor incidence in relevant markets
- Eligibility fraction for a drug (clinical criteria, timing, contraindications)
- Utilization fraction (number of treatment courses, retreatment rates)
- Pricing and reimbursement dynamics for acute obstetric care
- Competitive displacement limits due to entrenched alternatives and standard-of-care bundles
Scenario-based market projection (global peak sales)
All figures below are scenario-based peak sales estimates assuming successful commercialization and scaling.
| Scenario |
Time to first approvals |
Peak penetration (share of eligible tocolytic use) |
Peak sales (USD, global) |
Probability weight (investment-grade) |
| Bear |
8-12 years |
1-3% |
$25M-$75M |
30% |
| Base |
5-8 years |
3-7% |
$75M-$200M |
50% |
| Bull |
3-5 years |
7-12% |
$200M-$450M |
20% |
Interpretation: even under a bull case, a barusiban-like product in an obstetric indication typically struggles to reach blockbuster scale without major differentiation on either prevention of neonatal morbidity or a step-change in clinical decision-making.
What R&D and regulatory milestones would determine the investment path?
What must be demonstrated to unlock value?
The value driver for a relaunch is not receptor antagonism alone. It is clinical differentiation and regulatory credibility.
Milestones that gate commercial value:
- Demonstration of clinically meaningful improvement in obstetric outcomes beyond contraction metrics (e.g., reduced progression to delivery at key gestational thresholds)
- A trial design that aligns with current regulatory expectations for obstetric indications
- A safety profile that supports broad use within a constrained treatment window
- Comparative positioning against established tocolytics and protocol-based care
What de-risking strategy reduces timeline risk?
An investment-grade path generally relies on:
- Re-running the clinical development with endpoints that map to modern regulatory frameworks
- Selecting populations where the NK-1 mechanism plausibly drives effect size
- Designing comparative arms or robust historical comparisons to reduce adjudication friction
What is the commercial risk profile?
Clinical risk
- Obstetric indications often require large datasets for endpoint certainty.
- A treatment window limits dosing flexibility and can increase variance across sites.
Market risk
- Uptake depends on guideline integration and clinician familiarity.
- Formularies can be slow-moving for acute care, particularly for medicines that displace established standards.
Execution risk
- A relaunch requires operational continuity, IP strategy clarity, and partner alignment on trial design and endpoints.
Key Takeaways
- Barusiban is an NK-1 receptor antagonist with historical Phase 2 development focus in preterm labor.
- It is not a marketed product and lacks evidence of an active, globally visible late-stage program in public sources.
- Peak sales are likely to be modest relative to blockbuster standards under realistic adoption constraints in obstetric acute care.
- A base-case market outcome supports $75M-$200M peak global sales if barusiban reaches approvals in a 5-8 year window with credible differentiation.
FAQs
-
Is barusiban approved anywhere?
No public evidence supports marketing authorization for barusiban.
-
What mechanism does barusiban target?
Barusiban is an NK-1 receptor antagonist.
-
Which indication has historically anchored barusiban development?
Preterm labor and related obstetric outcomes.
-
What most limits barusiban’s peak sales upside?
Treatment-window constraints, protocol-driven care, and competitive tocolytic standards that cap eligible utilization and adoption.
-
What would be the highest-value proof point for a relaunch?
Demonstrating obstetric outcome improvement beyond uterine activity endpoints, with a trial design aligned to current regulatory expectations.
References
[1] U.S. National Library of Medicine. ClinicalTrials.gov. Study records for barusiban (search portal). https://clinicaltrials.gov/
[2] European Medicines Agency (EMA). Public assessment history and medicines database (barusiban search). https://www.ema.europa.eu/
[3] World Health Organization (WHO). International Clinical Trials Registry Platform (ICTRP) search for barusiban. https://trialsearch.who.int/
[4] PubChem. Barusiban substance records (mechanism and identifiers). https://pubchem.ncbi.nlm.nih.gov/
[5] Peer-reviewed clinical literature on NK-1 antagonists in preterm labor settings (general evidence base; search via PubMed for “barusiban preterm labor NK-1”). https://pubmed.ncbi.nlm.nih.gov/
